Global Pharmacovigilance Compliance

A centralized global safety model isn’t enough. Discover the country-specific pharmacovigilance requirements that determine whether your launch succeeds—or stalls under regulatory scrutiny.

Download the Fact Sheet →

 

As biopharmaceutical companies expand into multiple regions simultaneously, pharmacovigilance compliance grows more complex with every market added. Local language obligations, in-country representation, country-specific reporting pathways, and regional inspection readiness all sit outside the reach of a centralized global model—and gaps in any one of them can delay approvals, trigger findings, or compromise commercial timelines.

This fact sheet gives global PV, regulatory, and quality leaders a clear, side-by-side view of what local compliance actually requires across five of the most challenging launch regions.

Inside the fact sheet, you’ll find:

• A market-by-market breakdown of key local PV requirements across Japan (PMDA), EU5 + UK (EMA and national authorities), China (NMPA), the GCC (SFDA, UAE MOHAP, and regional authorities), and Canada (Health Canada)
• The most common compliance challenges companies face in each region—from Japanese literature monitoring to NMPA-compliant systems to Arabic-language surveillance
• The typical risks of underestimating local obligations, including delayed case intake, inspection findings, and scalability constraints during indication expansion
• A short self-assessment built around the questions every global PV leader should be able to answer with confidence
• How PrimeVigilance’s network of local PV experts across 170+ countries supports compliant operations from development through commercialization

If you’re planning expansion into Japan, China, the EU5, the GCC, or Canada—or operating in these markets and want to validate your current model—this fact sheet is built for you.

Download the fact sheet for a clear view of what’s required across five priority markets—and what to do if your current model falls short.